Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Total Non-current Assets
All assets not expected to be converted to cash within one year.
Zura Bio LimitedNASDAQ: ZURA
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 103.6% from a year ago
Total non-current assets stood at $1.64M at the end of Q1 FY2026, up 103.6% from a year earlier and down 0.1% from the prior quarter. Over 3 fiscal years it compounded at -22.3% a year.
Context
- Total non-current assets amounted to 0.7% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +103.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.64M USD
- Year-over-year change
- +107.6%
- 4-year CAGR
- -67.1%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.64M | +107.6% |
| FY2024 | 2024-12-31 | 789K | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 3.49M | -97.5% |
| FY2021 | 2022-03-31 | 139.4M | — |
Total Non-current Assets vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 total non-current assets of $1.64M is the 10th highest of the 11 companies compared; the peer median is $31.32M.
- Its year-over-year change of +103.6% is the 2nd highest of 11, against a peer median of -12.7%.
- Total non-current assets amounts to 0.7% of total assets for ZURA, versus a peer median of 20.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $53.4B | +427956.3% | +60.0% | 24.9% | |
| Mar 2026 | $136.29M | +70.1% | +3.5% | 43.3% | |
| Mar 2026 | $78.95M | -8.3% | -19.4% | 44.4% | |
| Mar 2026 | $38.51M | -22.2% | -21.4% | 28.5% | |
| Mar 2026 | $34.1M | +2.5% | -13.3% | 15.4% | |
| Mar 2026 | $28.53M | -46.2% | -14.2% | 11.6% | |
| Mar 2026 | $18.73M | -22.0% | -7.8% | 29.1% | |
| Mar 2026 | $5.01M | +102.8% | +171.0% | 5.1% | |
| Mar 2026 | $2.9M | -17.0% | -14.3% | 1.2% | |
ZURAZura Bio Limited | Mar 2026 | $1.64M | +103.6% | -22.3% | 0.7% |
SGMTSagimet Biosciences Inc. | Mar 2026 | $39K | -61.0% | -31.2% | 0.0% |
| Peer median (excluding ZURA) | $31.32M | -12.7% | -13.8% | 20.1% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.